GLPwatch
Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.
Gastroenterol Hepatol (N Y) · 2025
Last updated 2026-05-28| Journal | Gastroenterol Hepatol (N Y), 2025 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Mash, Obesity, Type 2 Diabetes, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 41658350 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.